AC Immune Announces Offerings and Issuance of up to 10 Million Common Shares

18-Jul-2018 - AC Immune SA announced that it is commencing offerings of up to 10 million new common shares of the Company with a nominal value of CHF 0.02 each. The Company intends to issue all new common shares against cash contributions as approved by the Company's shareholders.The Company plans to use the ...

Crenezumab Phase II cognition data in Alzheimer’s disease presented

21-Jul-2014 - AC Immune announced the presentation of data from two phase II studies investigating whether crenezumab (anti beta-amyloid antibody) can delay cognitive and functional decline in people with mild-to-moderate Alzheimer’s disease (AD) by its partner Genentech, a member of the Roche Group. The ...

AC Immune boosts its preclinical Alzheimer´s pipeline

18-Jan-2010 - AC Immune SA announced the in-licensing of an AMPAkine memory enhancer (ACI-518) from the State University of Moscow. This preclinical small molecule directly activates global memory function and provides AC Immune an entry into the new and exciting field of memory enhancers. It complements AC ...

AC Immune CEO Prof. Andrea Pfeifer awarded Swiss Life Sciences/High-Tech Entrepreneur of the Year 2009

26-Oct-2009 - AC Immune SA, announced today that Ernst &Young awarded Prof. Andrea Pfeifer the Entrepreneur of the Year® 2009 Switzerland in the category Life Sciences/High-Tech. This intensive competition has been conducted annually in Switzerland since 1998 as part of Ernst & Young’s global program ...

AC Immune and Bayer Schering Pharma collaborate in brain imaging for Alzheimer’s Disease

12-Oct-2009 - AC Immune SA announced that it has entered a collaboration with Bayer Schering Pharma on the diagnostic imaging of Alzheimer´s Disease. Bayer´s novel positron emission tomography (PET) tracer florbetaben will be applied for imaging beta-Amyloid plaques in the brain of patients undergoing the ...

AC Immune raises CHF 40 million in successful round C

Key appointments of Chief Financial Officer and Chief Medical Director

28-Jan-2009 - AC Immune SA announced that it has successfully completed its financing round C by raising CHF 40 million from existing investors and it has made two key appointments of Chief Financial Officer and Chief Medical Director. These developments build on the progress in its clinical pipeline ...